Home / Life Sciences

Legal News

Coronavirus (COVID-19)—EMA begins rolling review of regdanvimab (CT-P59)

Copyright © 2025 LexisNexis

Published on: 25 February 2021

Published by LNB News

LNB News 25/02/2021

Document Information

Issue Date: 25 February 2021

Published Date: 25 February 2021

Jurisdiction(s): United Kingdom

Article summary

The European Medicines Agency (EMA) has announced that the EMA's human medicines committee (CHMP) has started a rolling review of the monoclonal antibody regdanvimab (also known as CT-P59), a coronavirus (COVID-19) treatment being developed by Celltrion. The decision is based on preliminary results from an ongoing study looking at the ability of the medicine to treat coronavirus. The EMA will evaluate data as it becomes available and the rolling review will continue until there is enough evidence available for a formal marketing authorisation application.

Popular documents

Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an